5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole is used as a cyclooxygenase inhibitors on the angiogenesis and apoptosis.
SC-560 has been used as a cyclooxygenase-1 (COX-1) inhibitor to study its effects on prostaglandin E-2 (PGE2) signaling in ciliogenesis in zebrafish embryos. It has also been used as a selective inhibitor of COX-1 to study its role in PM10-induced endothelial dysfunction.
ChEBI: A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclo
xygenase (COX) inhibitors, SC-560 is selective for COX-1.
Highly selective cyclooxygenase-1 (COX-1) inhibitor (IC 50 values are 0.009 and 6.3 μ M for COX-1 and COX-2 respectively). Inhibits COX-1-derived platelet thromboxane B 2 , gastric PGE 2 and dermal PDE 2 production. Significantly reduces ovarian surface epithelial tumor growth in vivo . Orally active.
SC-560 (5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole) is a non-steroidal anti-inflammatory drug (NSAID). It is a lipophilic, diaryl heterocyclic compound. SC-560 acts as an effective antiviral agent against hepatitis C virus (HCV). It also has a potential to hinder prostaglandin E2 synthesis in neurons at nanomolar concentrations.
preincubation of cox-1 with sc-560 inhibited the conversion of arachidonic acid to pge2 in a concentration-dependent manner [1]. sc-560 was necessary to sustain a reduced basal level of pgi2 for an extended period. sc-560 inhibits cell proliferation and accelerates apoptosis which results in attenuated tumor growth [2].
oral dosing with either 10 or 30 mg/kg sc-560 1 hr before assay completely inhibited cox-1-derived platelet thromboxane b2, gastric pge2, and dermal pge2 production [1]. sc-560 can suppress ovarian surface epithelial tumor growth. tumor growth was suppressed in allografted mice treated with sc-560 for a longer period, but the reduction in tumor growth was less dramatic than the short-term treated [2].
0.009 μm for cox-1; 6.3 μm for cox-2
[1] daikoku t, wang d, tranguch s, morrow jd, orsulic s, dubois rn, dey sk. cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. cancer res. 2005 may 1;65(9):3735-44.
[2] christopher j. smith, yan zhang, carol m. koboldt, jerry muhammad, ben s. zweifel, alex shaffer, john j. talley, jaime l. masferrer, karen seibert, peter c. isakson. pharmacological analysis of cyclooxygenase-1 in inflammation. proc natl acad sci u s a. 1998 oct 27; 95(22): 13313–13318.
